Department of Respirology & Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy & Immunology, Shenzhen University School of Medicine, Shenzhen, China.
J Med Virol. 2021 May;93(5):3257-3260. doi: 10.1002/jmv.26829. Epub 2021 Feb 23.
Previous studies have revealed a diagnostic role of pathogen-specific IgA in respiratory infections. However, co-detection of serum specific IgA for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and common respiratory pathogens remains largely unexplored. This study utilizes a protein microarray technology for simultaneous and quantitative measurements of specific IgAs for eight different respiratory pathogens including adenovirus, respiratory syncytial virus, influenza virus type A, influenza virus type B, parainfluenza virus, mycoplasma pneumoniae, chlamydia pneumoniae, and SARS-CoV-2 in serum sample of patients with coronavirus disease 2019 (COVID-19). A total of 42 patients with COVID-19 were included and categorized into severe cases (20 cases) and nonsevere cases (22 cases). The results showed that co-detection rate of specific-IgA for SARS-CoV-2 with at least one pathogen were significantly higher in severe cases than that of nonsevere cases (72.2% vs. 46.2%, p = .014). Our study indicates that co-detection of IgA antibodies for respiratory pathogens might provide diagnostic value for the clinics and also be informative for risk stratification and disease management in patients with COVID-19.
先前的研究表明,病原体特异性 IgA 在呼吸道感染中有诊断作用。然而,对于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)和常见呼吸道病原体的血清特异性 IgA 的共同检测在很大程度上仍未得到探索。本研究利用蛋白质微阵列技术同时定量测量了 8 种不同呼吸道病原体的特异性 IgA,包括腺病毒、呼吸道合胞病毒、甲型流感病毒、乙型流感病毒、副流感病毒、肺炎支原体、肺炎衣原体和 SARS-CoV-2,用于检测 2019 年冠状病毒病(COVID-19)患者的血清样本。共纳入 42 例 COVID-19 患者,并分为重症病例(20 例)和非重症病例(22 例)。结果表明,重症病例中 SARS-CoV-2 与至少一种病原体的特异性 IgA 共同检测率明显高于非重症病例(72.2% vs. 46.2%,p=0.014)。我们的研究表明,呼吸道病原体 IgA 抗体的共同检测可能为临床提供诊断价值,也可能为 COVID-19 患者的风险分层和疾病管理提供信息。